Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1451 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Cmax of ABBV-1451.
Tmax of ABBV-1451.
β of ABBV-1451.
t1/2 of ABBV-1451.
AUCt of ABBV-1451.
AUCinf of ABBV-1451.
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 5 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 6 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo. |
| Part 2: Group 7 | EXPERIMENTAL | Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Part 2: Group 8 | EXPERIMENTAL | Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-1451 | DRUG | Injection |
| Placebo | OTHER | Injection |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. * Applies to Part 2 only: * For Japanese participants: \-- Participant must be first or second-generation Japanese of fu...
ABBV-1451 is an investigational small molecule being developed by AbbVie Inc. It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is administered as an infusion or injection and is being studied to evaluate its pharmacokinetics, safety, and tolerability.
ABBV-1451 is being studied for use in healthy volunteers. The ongoing Phase 1 trial is designed to evaluate the pharmacokinetics, safety, and tolerability of single ascending doses of ABBV-1451 when given as infusions or injections. Its potential therapeutic use has not yet been established.
ABBV-1451 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is currently conducting a Phase 1 clinical trial of ABBV-1451 in healthy adult participants in the United States.
ABBV-1451 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting healthy adult participants to study single ascending doses of the drug.
ABBV-1451 is being studied in one active Phase 1 clinical trial, identified as NCT07570147. This trial is a randomized, double-blind, controlled study evaluating the pharmacokinetics, safety, and tolerability of single ascending doses of ABBV-1451 infusions and injections in healthy adult participants. The trial is recruiting in the United States and aims to enroll 90 participants.
ABBV-1451 is the sole name provided for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.